Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
74.20M | 86.18M | 1.58B | 1.09B | 67.25M | Gross Profit |
73.36M | 83.42M | 1.43B | 1.02B | -234.33M | EBIT |
-587.16M | -684.30M | 833.07M | 276.89M | -296.98M | EBITDA |
-537.61M | -664.85M | 833.07M | 420.75M | -289.80M | Net Income Common Stockholders |
-521.96M | -615.06M | 515.84M | 528.58M | -298.67M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
990.38M | 1.52B | 2.40B | 708.14M | 736.86M | Total Assets |
1.40B | 1.92B | 2.80B | 1.95B | 918.76M | Total Debt |
90.14M | 124.54M | 127.97M | 133.56M | 66.56M | Net Debt |
-222.19M | -117.04M | -720.66M | -214.25M | -370.02M | Total Liabilities |
248.43M | 328.82M | 724.13M | 522.42M | 201.91M | Stockholders Equity |
1.15B | 1.59B | 2.08B | 1.43B | 716.85M |
Cash Flow | Free Cash Flow | |||
-453.65M | -800.36M | 1.60B | -69.41M | -197.49M | Operating Cash Flow |
-446.35M | -778.78M | 1.66B | -47.59M | -190.94M | Investing Cash Flow |
499.37M | 164.63M | -1.19B | -140.81M | -9.86M | Financing Cash Flow |
4.39M | 7.48M | 34.76M | 100.33M | 529.47M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $78.51B | 18.73 | 15.95% | 0.12% | 8.27% | 10.35% | |
75 Outperform | $142.50B | 306.43 | 2.28% | 2.69% | 6.16% | -91.54% | |
54 Neutral | $23.61B | ― | -3.38% | ― | -27.64% | -172.62% | |
51 Neutral | $1.01B | ― | -38.09% | ― | -13.90% | 16.56% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
48 Neutral | $13.03B | ― | -28.77% | ― | -52.75% | 25.00% | |
39 Underperform | $1.27B | ― | 30.06% | ― | -30.65% | 77.62% |
On January 24, 2025, Vir Biotechnology announced the departure of their Executive Vice President and Chief Technology Officer, Ann (Aine) M. Hanly, Ph.D., effective February 26, 2025. The company appointed Maninder Hora, Ph.D. as her successor, effective February 27, 2025, which indicates a strategic shift in leadership that could impact the company’s operational dynamics and stakeholder confidence.
Vir Biotechnology announced promising Phase 1 trial results for its dual-masked T-cell engagers, VIR-5818 and VIR-5500, targeting HER2-expressing solid tumors and PSMA in metastatic castration-resistant prostate cancer respectively. The data showed compelling early clinical responses and a favorable safety profile, with no dose-limiting toxicities and no severe cytokine release syndrome observed. The findings support the potential of Vir’s PRO-XTEN masking technology to improve treatment efficacy and tolerability, which could lead to novel therapeutic options for cancer patients.